PredictImmune, developers of pioneering prognostic tools for guiding treatment options in immune-mediated diseases, confirmed that it has entered into a commercial partnership with Theradiag, a pioneering European diagnostic company specialising in in vitro diagnostics and theranostics for autoimmune diseases and the monitoring of biotherapies, specifically for IBD patients. Under the agreement, Theradiag, (which is quoted on the Paris Stock Exchange on Euronext Growth – ISIN: FR0004197747, Ticker: ALTER) will have the exclusive rights to promote, license and distribute PredictSURE IBD to local gastroenterologists and commercial and hospital laboratories in France, Belgium, Luxemburg, Switzerland and the Maghreb countries; providing access to the world’s first validated prognostic test for IBD patients across the region.

Read More